Breaking up Mucus Plugs in Asthma Authors: William W. Busse, Nizar N. Jarjour Published: 2024 Mucus plugs lead to bad outcomes in asthma. In fatal asthma, mucus plugs occlude airways, blocking gas exchange to cause asphyxia and death (1, 2). In exacerbations, mucus plugs occlude major airways and contribute to air trapping, atelectasis, and treatment unresponsiveness (3). These severe consequences reflect the profound impact of mucus plugs in asthma and the need for treatment advances. The identification of phenotypic and endotypic characteristics of populations with asthma who are at risk for mucus plugs is a key first step to improved care. Dunican and colleagues (4) from the National Heart, Lung and Blood Institute Severe Asthma Research Program developed a bronchopulmonary segment–based scoring system with multidetector computed tomography for mucus plugs, which were most prominent in severe asthma, correlated with reduced FEV1, and paralleled sputum eosinophils and release of the granule protein eosinophil peroxidase. Mechanistic in vitro modeling suggested that eosinophil peroxidase–generated oxidants crosslink mucin cysteine thiol groups to form mucus plugs (4). Moreover, mucus plugs can persist for 3 years in the same airways of affected patients with asthma (5). Persistence of mucus plugs and airflow obstruction correlated with blood and sputum eosinophils, suggesting a role for Type 2(T2) inflammation (5). Ongoing treatment with bronchodilators and inhaled or systemic corticosteroids had no apparent effect on mucus plug presence. Jaramillo and colleagues (6) detailed the complex processes that lead to mucus plug formation and treatment ineffectiveness, which may include airway epithelial cell goblet cell hyperplasia and mucin hypersecretion; these processes are regulated, at least in part, by T2 cytokines, particularly IL-13, acting through a JAK-1/STAT-6 pathway, and eosinophils. Furthermore, mucus is normally removed from the airway by escalator actions of beating cilia and is altered in severe asthma. Therefore, dysfunction of many integrated airway processes creates risks for mucus plug formation, particularly in severe asthma. In this issue of the Journal, Boomer and colleagues (pp. 1409–1420) provide new insight into mucus plug formation in asthma (7). A strength of their work is an integration of multiple complementary factors, including clinical parameters, immunohistological characterization of mucosal biopsies, determination of transcriptomic products, in vitro culture to define IL-13 effects on epithelial cell function and regulation of mucin formation, and treatment with in vitro modeling with the IL-4Rα antagonist dupilumab. Their approach to establish the complex responses associated with mucus plug formation in asthma is reflected by the investigative design. Three patient populations—healthy (n = 18), nonsevere asthma (n = 11), and severe asthma (n = 20)—were evaluated using lung computed tomography scans for mucus plugs. Bronchoscopy provided endobronchial biopsies to describe features of airway remodeling and epithelial cells for air–liquid interface (ALI) culture. Although extensive and comprehensive assessments were made, we will focus on a few key outcomes: ciliated cell characteristics and function, MUC5AC gene expression, and IL-13 effects on epithelial cell function. In addition, in vitro incubations with dupilumab and the T2 cytokine IL-13 tested the potential effectiveness of therapeutic targets associated with mucus plug formation. Finally, in vitro responses were evaluated in relation to clinical characteristics to create a bedside-to-bench-to-bedside guide to mechanisms and treatment. The mucus score index was greater in patients with severe asthma versus healthy control subjects as shown by Boomer and colleagues in Table 2 (P < 0.001) (7), thus validating an at-risk asthma population for study and as noted by Dunican and colleagues (4) and Tang and colleagues (5). Increased mucus plug scores were associated with a greater expression of MUC5AC in endobronchial biopsies from participants with severe asthma in Figure 1B from Boomer and colleagues (7); considerable variability in MUC5AC expression in severe asthma existed, likely reflecting heterogeneity in the risk for mucus plugs. The number of ciliated cells (Foxj1 + cells) was also decreased in severe asthma (Figure 1C) in Boomer and colleagues (7). Airway histology in severe asthma showed a decrease in ciliated escalator function and increased mucin formation and expression of MUC5AC to indicate a susceptible setting for mucus plug formation. Finally, airway remodeling correlated with T2 biomarkers, eosinophils and fractional exhaled nitric oxide, to imply putative mediators for mucus plug development. Formation and potential treatment of mucus plugs in asthma. T2 inflammation contributes to mucus plug formation by 1) IL-13 interference of cilia beat frequency to promote the retention of airway mucus; 2) IL-13 activation of MUC5AC to promote mucin generation; and 3) the release of EPX to cross-link mucin disulfide groups and form mucus plugs. Optimal treatment may require biologics directed at eosinophils (anti-IL-5IL-5R) and anti-IL-4Rα to regulate mucin formation to block mucus plug formation. EPX = eosinophil peroxidase. ALI incubations of airway epithelial cells with IL-13, a known driver of epithelial cell injury, modeled how altered ciliated cell function and MUC5AC expression may relate to mucus plug formation by T2 inflammation. Although in vitro incubation experiments may not fully replicate in vivo events, they provide an informative window into the effects of a key T2 cytokine, IL-13, on ciliated cell function and MUC5AC expression and, consequently, risks for mucus plug formation. IL-13 significantly increased in MUC5AC expression and decreased cilia in Figure 3 from Boomer and colleagues (7) and cilia beat frequency see in Figure 4 (7), mirroring features from mucosal biopsies and factors regulating mucus plug formation (Figure 1). These in vitro effects were not limited—or, necessarily, more apparent—with epithelial cells from severe asthma. Although the in vitro effects of IL-13 to alter cilia function and MUC5AC expression were noted, no striking or consistent differences emerged between healthy versus asthma sources. Dupilumab increased, or restored, cilia (α-acetyl-tubulin expression) in healthy subjects and in subjects with asthma. In contrast, dupilumab’s reduction of IL-13–stimulated MUC5AC expression was variable and not unique in asthma. In summary, the authors demonstrated that airway epithelium is thickened and proliferating in severe asthma and is associated with increased MUC5AC expression and a loss of ciliated cell function to contribute to mucus plug formation. From ALI cultures with IL-13, dupilumab primarily restored cilia function. How do we translate these findings into therapeutic strategies? Alteration in mucus plug presence is more complex and comprehensive than the IL-5 pathway alone. Reductions in the presence of mucus plugs in severe asthma have followed dupilumab treatment (8,9) and with tezepelumab (10), suggesting the participation of IL-13 and thymic stromal lymphopoietin and its downstream pathways as well. Consequently, Venegas Garrido and colleagues (3) suggest directive insights to therapeutic approaches to control mucus plugs in severe asthma on the basis of their experience with over 200 patients. First, the predominant cause of airflow obstruction needs to be established: eosinophilia versus mucus. When airway eosinophilia is prominent, anti-IL-5/IL-5R biologics are recommended. If airflow obstruction is predominated by mucus, an IL-4Rα biologic is suggested but can be expanded to tezepelumab (3). The findings of Boomer and colleagues (7) coincide with these recommendations and substantiate that mucus plug formation represents a complex heterogeneous mixture of cilia escalator pathology, overexpression of MUC5AC with mucin hypersecretion, and T2 inflammation with eosinophils (Figure 1). Therefore, effectively targeting mucus plugs will require a combination approach with anti-IL-5/IL-5R as well as anti-thymic stromal lymphopoietin and anti-IL-4Rα biologics. Although combined biologic treatment adds complexity to management, this undertaking is warranted, given the risks of mucus plugs in asthma.